CN113009122B - 用于测定自闭症谱系病症风险的方法和系统 - Google Patents

用于测定自闭症谱系病症风险的方法和系统 Download PDF

Info

Publication number
CN113009122B
CN113009122B CN202110060437.4A CN202110060437A CN113009122B CN 113009122 B CN113009122 B CN 113009122B CN 202110060437 A CN202110060437 A CN 202110060437A CN 113009122 B CN113009122 B CN 113009122B
Authority
CN
China
Prior art keywords
asd
acid
metabolites
metabolite
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110060437.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113009122A (zh
Inventor
U·盖根穆勒
D·达米安
M·帕库拉
M·A·德普里斯托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Labcorp Holdings Inc
Original Assignee
Laboratory Corp of America Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/493,141 external-priority patent/US20150294081A1/en
Application filed by Laboratory Corp of America Holdings filed Critical Laboratory Corp of America Holdings
Publication of CN113009122A publication Critical patent/CN113009122A/zh
Application granted granted Critical
Publication of CN113009122B publication Critical patent/CN113009122B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Ecology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
CN202110060437.4A 2014-04-11 2015-04-10 用于测定自闭症谱系病症风险的方法和系统 Active CN113009122B (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201461978773P 2014-04-11 2014-04-11
US61/978,773 2014-04-11
US201462002169P 2014-05-22 2014-05-22
US62/002,169 2014-05-22
US14/493,141 US20150294081A1 (en) 2014-04-11 2014-09-22 Methods and systems for determining autism spectrum disorder risk
US14/493,141 2014-09-22
US14/633,558 2015-02-27
US14/633,558 US9176113B1 (en) 2014-04-11 2015-02-27 Methods and systems for determining autism spectrum disorder risk
CN201580028014.7A CN106714556B (zh) 2014-04-11 2015-04-10 用于测定自闭症谱系病症风险的方法和系统
PCT/US2015/025247 WO2015157601A1 (en) 2014-04-11 2015-04-10 Methods and systems for determining autism spectrum disorder risk

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580028014.7A Division CN106714556B (zh) 2014-04-11 2015-04-10 用于测定自闭症谱系病症风险的方法和系统

Publications (2)

Publication Number Publication Date
CN113009122A CN113009122A (zh) 2021-06-22
CN113009122B true CN113009122B (zh) 2025-01-17

Family

ID=54264902

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110060437.4A Active CN113009122B (zh) 2014-04-11 2015-04-10 用于测定自闭症谱系病症风险的方法和系统
CN201580028014.7A Active CN106714556B (zh) 2014-04-11 2015-04-10 用于测定自闭症谱系病症风险的方法和系统

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580028014.7A Active CN106714556B (zh) 2014-04-11 2015-04-10 用于测定自闭症谱系病症风险的方法和系统

Country Status (6)

Country Link
US (3) US9176113B1 (https=)
EP (2) EP3954991A3 (https=)
JP (5) JP6550124B2 (https=)
CN (2) CN113009122B (https=)
CA (3) CA3157221A1 (https=)
WO (1) WO2015157601A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10060932B2 (en) * 2013-07-09 2018-08-28 Stemina Biomarker Discovery, Inc. Biomarkers of autism spectrum disorder
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
CA2973116C (en) * 2015-01-09 2023-08-15 Global Genomics Group, LLC Blood based biomarkers for diagnosing atherosclerotic coronary artery disease
US10525020B2 (en) 2015-02-11 2020-01-07 Laboratory Corporation Of America Holdings Metabolic markers of attention deficit hyperactivity disorder
AU2016268158B2 (en) 2015-05-22 2022-03-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
WO2017197252A1 (en) * 2016-05-13 2017-11-16 Stemina Biomarker Discovery, Inc. Autism subsets
WO2018089794A1 (en) * 2016-11-11 2018-05-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for changing metabolite levels in a subject
WO2019032573A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER
US12025596B2 (en) 2018-02-19 2024-07-02 The Regents Of The University Of Colorado, A Body Corporate 6-oxo-pipecolic acid quantitation by mass spectrometry
AU2019338183A1 (en) * 2018-09-11 2021-03-11 Metabolon, Inc. Mass spectrometry assay method for detection and quantitation of microbiota-related metabolites
CN110487922B (zh) * 2018-12-17 2022-09-27 广西中烟工业有限责任公司 一种烟叶中苏糖酸和苏糖酸酯的gc-ms分析方法
EP3947732A4 (en) * 2019-04-05 2023-01-11 Arizona Board of Regents on behalf of Arizona State University DIAGNOSIS OF MATERNAL RISK OF HAVING A CHILD WITH AUTISM SPECTRUM DISORDER
EP3948277A4 (en) * 2019-04-05 2023-05-24 Arizona Board of Regents on behalf of Arizona State University METABOLITES AS DIAGNOSTICS OF AUTISTIC SPECTRUM DISEASE IN CHILDREN WITH GASTROINTESTINAL SYMPTOMS
JP2022534369A (ja) * 2019-05-31 2022-07-29 メタボロン，インコーポレイテッド 代謝物を検出するための質量分析アッセイ法
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
CN112180005B (zh) * 2020-09-01 2022-10-04 上海市疾病预防控制中心 一种预测鉴定生物样本中酰基肉碱的方法及其应用
WO2022056646A1 (en) * 2020-09-21 2022-03-24 Molecular You Corporation Method of diagnosis and treatment of autism spectrum disorder
CN113539478B (zh) * 2021-06-24 2023-04-07 山西医科大学 基于代谢组学的深静脉血栓形成预测模型的建立方法
CN115938490B (zh) * 2023-03-07 2023-06-06 之江实验室 一种基于图表示学习算法的代谢物鉴定方法、系统和设备
WO2026011154A1 (en) * 2024-07-03 2026-01-08 Arizona Board Of Regents On Behalf Of Arizona State University Diagnostic tests for autism, gut dysbiosis, gut disorders, and neurological disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011010104A1 (en) * 2009-07-22 2011-01-27 Imperial Innovations Limited Methods

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230767A (en) 1978-02-08 1980-10-28 Toyo Boseki Kabushiki Kaisha Heat sealable laminated propylene polymer packaging material
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5686311A (en) 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
AU2001253886A1 (en) * 2000-04-12 2001-10-30 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
US20040121305A1 (en) 2002-12-18 2004-06-24 Wiegand Roger Charles Generation of efficacy, toxicity and disease signatures and methods of use thereof
WO2004059293A2 (en) 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20050101023A1 (en) 2003-03-28 2005-05-12 Rogers James A. Methods for diagnosing urinary tract and prostatic disorders
GB0504096D0 (en) 2005-02-28 2005-04-06 Tipogen As Method
US7604948B2 (en) 2005-05-05 2009-10-20 The Regents Of The University Of California Biomarkers for diagnosing an autism spectrum disorder
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
US20070255113A1 (en) 2006-05-01 2007-11-01 Grimes F R Methods and apparatus for identifying disease status using biomarkers
EP2052255A2 (en) 2006-08-18 2009-04-29 Huntington Medical Research Institutes Methods of determining levels of free amino acids and dipeptides and diagnosing alzheimer's diseases
JP5306345B2 (ja) 2007-07-26 2013-10-02 フェノメノーム ディスカバリーズ インク 自閉症スペクトラム障害の診断、リスク評価、及びモニタリングを行うための方法
US20120004854A1 (en) 2008-05-28 2012-01-05 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
ES2875764T3 (es) * 2009-08-14 2021-11-11 Univ California Métodos para diagnosticar y tratar autismo
WO2011139914A1 (en) 2010-04-29 2011-11-10 Wisconsin Alumni Research Foundation Metabolic biomarkers of autism
CA2866407A1 (en) * 2012-03-05 2013-09-12 Berg Llc Compositions and methods for diagnosis and treatment of pervasive developmental disorder
WO2013132074A2 (en) 2012-03-09 2013-09-12 Integragen A genotyping test for assessing risk of autism
US20140045702A1 (en) * 2012-08-13 2014-02-13 Synapdx Corporation Systems and methods for distinguishing between autism spectrum disorders (asd) and non-asd development delay
WO2014036182A2 (en) * 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011010104A1 (en) * 2009-07-22 2011-01-27 Imperial Innovations Limited Methods

Also Published As

Publication number Publication date
JP2023178345A (ja) 2023-12-14
JP6550124B2 (ja) 2019-07-24
US20150293072A1 (en) 2015-10-15
CN106714556A (zh) 2017-05-24
US9176113B1 (en) 2015-11-03
JP2021103177A (ja) 2021-07-15
EP3151665A4 (en) 2018-04-25
EP3954991A2 (en) 2022-02-16
CN113009122A (zh) 2021-06-22
JP2019200210A (ja) 2019-11-21
CA2945528C (en) 2019-03-12
EP3151665A1 (en) 2017-04-12
EP3954991A3 (en) 2022-05-18
CA3030255A1 (en) 2015-10-15
JP2017510821A (ja) 2017-04-13
CN106714556B (zh) 2021-01-26
US20240019417A1 (en) 2024-01-18
CA2945528A1 (en) 2015-10-15
US20160091481A1 (en) 2016-03-31
CA3030255C (en) 2022-07-05
EP3151665B1 (en) 2021-03-10
CA3157221A1 (en) 2015-10-15
WO2015157601A1 (en) 2015-10-15
JP2025172836A (ja) 2025-11-26

Similar Documents

Publication Publication Date Title
CN113009122B (zh) 用于测定自闭症谱系病症风险的方法和系统
US20240230622A9 (en) Methods and Systems for Determining Autism Spectrum Disorder Risk
US11268966B2 (en) Biomarkers of autism spectrum disorder
US8653006B2 (en) Metabolite biomarkers for the detection of esophageal cancer using NMR
Liang et al. Metabolomics of alcoholic liver disease: a clinical discovery study
CN111279193B (zh) 白塞氏病诊断试剂盒及检测尿中代谢物差异的方法
Liang et al. Novel liquid chromatography-mass spectrometry for metabolite biomarkers of acute lung injury disease
CN115684451A (zh) 基于代谢组学的食管鳞癌淋巴结转移诊断标志物及其应用
HK40051641A (zh) 用於测定自闭症谱系病症风险的方法和系统
HK40051641B (zh) 用於测定自闭症谱系病症风险的方法和系统
CN115436633A (zh) 一种结直肠癌检测的生物标志物及其应用
HK40065445A (en) Methods and systems for determining autism spectrum disorder risk
CN116804676A (zh) 一种与哮喘相关的生物标志物及其应用
CN117647650A (zh) 预测过敏反应严重程度的生物标志物及其用途和试剂盒

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40051641

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant